RJ - BMY: Key Takeaways from Raymond James Fireside Chat | BMY Message Board Posts

Bristol-Myers Squibb Co.

  BMY website

BMY   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  6379 of 6714  at  3/3/2021 3:38:24 PM  by

Biotech2050


 In response to msg 6378 by  Doolen
view thread

Re: RJ - BMY: Key Takeaways from Raymond James Fireside Chat

The omission might have been done with intent. Think about it. Keep it low profile to keep revlimid patent challengers (which settled for gradual market penetration in 2022) hopeful that they will soon have a market share in myeloma but KOLs will want CC-220 CC-480 for their clients once they are approved.
 
same strategy being applied with nivolumab subcutaneous updates which might be a new formulation. 
At times silence is golden  


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 0
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board








Financial Market Data provided by
.
Loading...